LinkGevity

LinkGevity is a biotech company developing first-in-class anti-necrotic therapeutics. Cellular necrosis is an underlying driver of disease across kidney failure, cardiovascular events, neurodegeneration, and organ transplant rejection — contributing to approximately 30% of global mortality, due to cardiovascular, ki

Our lead programme, LINK-001 Anti-Necrotic™, was developed through an internal computational discovery pipeline. The programme is on track for FDA filing for kidney disease, and boasts leading kidney experts from Harvard and Mayo Clinic as advisors.

Later this year, we will send LINK-001 to space for microgravity testing in collaboration with the UK Space Agency and Delta Biosciences — investigating how the microgravity environment affects drug crystallography, protein interaction, and cellular behaviour relevant to necrotic pathways. We co-hosted the UK's first Biotech in Space conference alongside UKSA, Delta Biosciences, AWS, and other partners.

LinkGevity sits at the intersection of pharmaceutical R&D, artificial intelligence, and space-enabled science. We bring a real-world drug programme as a testbed for digital and space-based innovation, and we are seeking consortium partners with complementary capabilities in AI/ML for drug discovery, space experimentation platforms, anti-necrotics use cases, and science translation.